The Innovative Medicines Initiative (IMI)


imi logoThe PreDiCT-TB Project is funded by the Innovative Medicines Initiative (IMI), a large-scale public-private partnership between the European Union and the pharmaceutical industry association EFPIA.

IMI aims to boost biopharmaceutical innovation in Europe and to speed up the development of better and safer medicines for patients.  Through its unique and innovative funding scheme, IMI supports research projects in the areas of safety and efficacy, knowledge management and education and training.

In addition to the large biopharmaceutical companies, the participating research consortia include small- and medium-sized enterprises, patient organisations, academia and other research organisations, hospitals and public authorities.

The European Commission’s Seventh Framework Programme contributes €1 billion to the IMI research programme.  That amount is matched by in kind contributions worth at least another €1 billion from the pharmaceutical companies that are members of EFPIA, the European Federation of Pharmaceutical Industries and Associations.

Find out more: www.imi.europa.eu

Consortium Partners

PreDiCT-TB brings together twenty-one leading European research partners in tuberculosis from both Industry and Academia

View More

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115337, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.

The communication contained within this site reflects the author’s view and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained therein.